Bio-Rad Laboratories shares are trading higher after Citigroup maintained a Buy rating on the stock and raised its price target from $400 to $450.
Portfolio Pulse from Benzinga Newsdesk
Bio-Rad Laboratories shares rose following Citigroup's decision to maintain a Buy rating and increase the price target from $400 to $450.
November 01, 2024 | 7:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Rad Laboratories shares are trading higher after Citigroup maintained a Buy rating and raised its price target from $400 to $450.
The increase in price target and maintained Buy rating by Citigroup is a positive signal for investors, likely leading to increased buying interest and a short-term rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100